<p><strong>美敦力</strong>（MDT -0.68%）今天不太受歡迎，儘管其歷史上股息收益率約為 3%。不過，該公司正在努力改善其業務表現，預計將會有更強勁的業績。這可能使美敦力成為今天你可以購買的最佳醫療保健股票之一。</p>
<h2>美敦力處於低迷狀態</h2>
<p>作為一家醫療設備製造商，投資於研發是美敦力業務的關鍵方面。然而，研發本身就是一個不穩定的努力，更不用説它是一個耗時且昂貴的過程。今天圍繞美敦力的低迷看法至少部分與其經歷了一個發展乾旱期有關。然而，隨着公司新的外科手術機器人和心臟消融系統開始獲得關注，這種情況正在開始改變。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzAyMDgvMjRfMDlfMTQtd29vZGVuLWJsb2Nrcy1zcGVsbGluZy1vdXQtYnVsbC1hbmQtYmVhci1fbWYtZGxvYWQtZ2V0dHlpbWFnZXMtMTMxNjEyOTA3NC0xMjAxeDY1Ni05Y2ZmNDcyLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzAyMDgvMjRfMDlfMTQtd29vZGVuLWJsb2Nrcy1zcGVsbGluZy1vdXQtYnVsbC1hbmQtYmVhci1fbWYtZGxvYWQtZ2V0dHlpbWFnZXMtMTMxNjEyOTA3NC0xMjAxeDY1Ni05Y2ZmNDcyLmpwZyZ3PTcwMA"/></p>
<p>圖片來源：Getty Images。</p>
<p>然而，這只是圍繞美敦力投資論點的開始。它還試圖專注於其最盈利的業務。在這方面的下一個重大舉措將是剝離其糖尿病治療部門，這將立即增加收益。這是因為醫療巨頭其他業務（心血管、外科醫療和神經科學領域）的利潤率高於糖尿病部門。</p>
<p>然而，從大局來看，隨着新產品的上線，該公司的盈利增長可能會快於華爾街目前的預期。更高的利潤率本質上應該有助於加速來自研發開發的收入增長。總的來説，你今天可以獲得高收益，同時等待投資者跟上美敦力業務改善的基本面。當他們跟上時，市場可能會迅速從對該股票的看跌轉向看漲。</p>

美敦力

<p>美敦力（MDT）目前被低估，儘管其股息收益率約為 3%。該公司正在通過新的外科手術機器人和心臟消融系統來提升業務表現。計劃中的糖尿病部門分拆預計將提升盈利，因為剩餘部門的利潤率更高。隨着新產品的推出，美敦力的盈利增長可能會超出華爾街的預期，從而可能將市場情緒從看跌轉向看漲</p>

<p><strong>Medtronic</strong>(MDT -0.68%) is out of favor today, noting it has a historically high dividend yield of around 3%. The company is working on improving its business performance, however, and stronger results are likely on tap. That could make Medtronic one of the best healthcare stocks you can buy today.</p>
<div class="lb-trans"><p><strong>美敦力</strong>（MDT -0.68%）今天不太受歡迎，儘管其歷史上股息收益率約為 3%。不過，該公司正在努力改善其業務表現，預計將會有更強勁的業績。這可能使美敦力成為今天你可以購買的最佳醫療保健股票之一。</p>
</div><h2>Medtronic was in a funk</h2>
<div class="lb-trans"><h2>美敦力處於低迷狀態</h2>
</div><p>As a medical device maker, investing in research and development is a key aspect of Medtronic's business. Only R&amp;D is an inherently lumpy effort, not to mention a time-consuming and expensive one. At least part of the downbeat view around Medtronic today is related to the fact that it went through a development dry spell. That, however, is beginning to change with the company's new surgical robots and cardiac ablation systems starting to gain traction.</p>
<div class="lb-trans"><p>作為一家醫療設備製造商，投資於研發是美敦力業務的關鍵方面。然而，研發本身就是一個不穩定的努力，更不用説它是一個耗時且昂貴的過程。今天圍繞美敦力的低迷看法至少部分與其經歷了一個發展乾旱期有關。然而，隨着公司新的外科手術機器人和心臟消融系統開始獲得關注，這種情況正在開始改變。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzAyMDgvMjRfMDlfMTQtd29vZGVuLWJsb2Nrcy1zcGVsbGluZy1vdXQtYnVsbC1hbmQtYmVhci1fbWYtZGxvYWQtZ2V0dHlpbWFnZXMtMTMxNjEyOTA3NC0xMjAxeDY1Ni05Y2ZmNDcyLmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F830208%2F24_09_14-wooden-blocks-spelling-out-bull-and-bear-_mf-dload-gettyimages-1316129074-1201x656-9cff472.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><p>That, however, is just the start of the investment thesis around Medtronic. It has also been attempting to focus on its most profitable businesses. The next big move on this front will be the spinoff of its diabetes treatment division, which will be immediately accretive to earnings. That's because the rest of the healthcare giant's businesses (in the cardiovascular, medical surgical, and neuroscience niches) have higher profit margins than does the diabetes division.</p>
<div class="lb-trans"><p>然而，這只是圍繞美敦力投資論點的開始。它還試圖專注於其最盈利的業務。在這方面的下一個重大舉措將是剝離其糖尿病治療部門，這將立即增加收益。這是因為醫療巨頭其他業務（心血管、外科醫療和神經科學領域）的利潤率高於糖尿病部門。</p>
</div><p>The big picture here, however, is that as new products come on line, the company's earnings growth could be faster than Wall Street is currently expecting. Higher profit margins, essentially, should help supercharge the increased revenues from R&amp;D developments. All in, you get to collect a high yield today while you wait for investors to catch up to the improving fundamentals of Medtronic's business. When they do catch up, the market could quickly go from being bearish on the stock to being bullish.</p>
<div class="lb-trans"><p>然而，從大局來看，隨着新產品的上線，該公司的盈利增長可能會快於華爾街目前的預期。更高的利潤率本質上應該有助於加速來自研發開發的收入增長。總的來説，你今天可以獲得高收益，同時等待投資者跟上美敦力業務改善的基本面。當他們跟上時，市場可能會迅速從對該股票的看跌轉向看漲。</p>
</div>

美敦力（MDT）是您今天可以購買的最佳醫療保健股票之一的原因之一